Table 1.
Baseline demographic and clinical characteristics
| Total (n = 220) | EEI (n = 110) | Regular care (n = 110) | |
|---|---|---|---|
| Age at onset of first-episode psychosis, y, mean (SD) | 22.4 (4.4) | 21.9 (4.1) | 22.9 ± 4.7 |
| Male, n (%) | 151 (68.6%) | 75 (68.2%) | 76 (69.1%) |
| Single, n (%) | 200 (90.9%) | 103 (93.6%) | 97 (88.2%) |
| High school education or less, n (%) | 103 (46.8%) | 53 (48.2%) | 50 (45.4%) |
| Duration of untreated psychosis, wk, mean (SD) | 49.3 (123.6; median: 11.6) | 52.4 (148.8; median: 8.3) | 46.3 (92.7; median: 12.7) |
| Low (≤12 wk) duration of untreated psychosis, n (%)a | 73 (47.1%) | 38 (22.5%) | 35 (24.5%) |
| Primary diagnosis of schizophrenia spectrum, n (%) | 143 (65.0%) | 74 (67.3%) | 69 (62.7%) |
| Secondary diagnosis of substance abuse/ dependence, n (%) | 105 (47.7%) | 52 (47.3%) | 53 (48.2%) |
| Antipsychotic dose in chlorpromazine equivalents, mg, mean (SD) | 314.6 (332.6) | 299.9 (350.1) | 329.7 (342.9) |
| SAPS total score, mean (SD) | 6.5 (9.7; n = 216) | 7.1 (10.4; n = 107) | 6.0 (8.9; n = 109) |
| SANS total score, mean (SD) | 13.8 (11.6; n = 204) | 13.6 (10.4; n = 103) | 14.0 (12.8; n = 101) |
| Positive symptom remission, n (%) | 161 (73.2%) | 81 (73.6%) | 80 (72.7%) |
| Negative symptom remission, n (%) | 107 (48.6%) | 53 (48.2%) | 54 (49.1%) |
| Total symptom remission, n (%) | 92 (41.8%) | 45 (40.9%) | 47 (42.7%) |
Note: EEI, extended early intervention; SAPS, Scale for Assessment of Positive Symptoms; SANS, Scale for Assessment of Negative Symptoms.
aPercentages calculated out of 155 for which duration of untreated psychosis status was available.